Baird Sees More Upside on Regeneron Pharma (REGN), Lifts Price Target

Baird reiterated its Outperform rating on Regeneron Pharma (NASDAQ: REGN) and bumped its price target from $120 to $125, saying despite the 115% YTD run-up they remain buyers, especially after ACC updates confirmed REGN727 as a major player in the emerging anti-PCSK9 drug class.

"While some postulated yesterday that AMGN’s anti-PCSK9 has an edge, in our view the data and details simply do not support that assertion. We continue to believe that right now the only thing that differentiates is time to market, with REGN727 ahead by a year."

For an analyst ratings summary and ratings history on Regeneron Pharma click here. For more ratings news on Regeneron Pharma click here.

Shares of Regeneron Pharma closed at $119.96 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Regeneron Pharma (REGN) PT Raised to $756 at Bernstein SocGen Group
• Piper Sandler Reiterates Overweight Rating on Estee Lauder (EL), 'F4Q26 Preview'
• New Street Research Upgrades Micron Technology (MU) to Buy